Most recent articles by:

Ian Chan

Ian Chan is the co-founder and CEO of Abpro, a biotechnology company aimed to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Ian has been with Abpro since its inception in 2007, when he and his brother, Eugene, founded the company. Ian received an AB from Brown University and MBA from Harvard University.
- Advertisement -

Monoclonal Antibodies Offer Much Needed Protection for the Immunocompromised Population

Even though we don’t feel it or notice it, each minute, our bodies’ immune systems are hard at work eliminating abnormal cells,...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm
- Advertisement -